Join Columbia Technology Ventures (CTV) for a discussion and Q&A with Doug Cole, managing partner of Flagship Ventures, a life science venture fund with over $1.4 billion under management and a new $574 million fund devoted to early-stage therapeutics, health technologies and sustainability. In a live interview with CTV’s Director Orin Herskowitz, Doug will discuss Flagship Ventures’ perspective on opportunities and challenges within the venture investment landscape, current trends, past experiences with early-stage investing, its VentureLabs Fellows program, and building a career as a venture capitalist.
Doug Cole, MD is a managing partner at Flagship Ventures. He has previously served as Program Executive at Vertex Pharmaceuticals, Inc., in Cambridge, MA and as Medical Director at Cytotherapeutics, in Providence, RI. Prior to his work at Cytotherapeutics, Doug served as Instructor in Neurology at Harvard Medical School and an Assistant in Neurology at the Massachusetts General Hospital in Boston, MA.
At Flagship, Doug has led investments in Agios Pharmaceuticals (NASDAQ: AGIO), Alvine Pharmaceuticals, Avedro, CombinatoRx, Concert Pharmaceuticals (NASDAQ: CNCE), Denali Therapeutics, Editas, Quanterix Corporation, Receptos (NASDAQ: RCPT; acquired by Celgene, Inc.), Seventh Sense Biosystems, Tetraphase Pharmaceuticals (NASDAQ: TTPH), and Torque Therapeutics. He is a co-founder of Flagship portfolio companies Ensemble Therapeutics, Permeon Biologics, Moderna Therapeutics, and Syros Pharmaceuticals.
Orin Herskowitz, VP of Intellectual Property and Tech Transfer for Columbia University and Executive Director of Columbia Technology Ventures (CTV), is also an Adjunct Professor at Columbia’s Business and Engineering Schools. He has been a Board Member or Advisor to a number of innovation and entrepreneurship-focused initiatives in NYC, including the NYC Media Lab, the Coulter Translational Partnership, and PowerBridgeNY.
Learn about out new health tech program at the HITLAB Innovators Summit. In Q1 2016, NYCEDC will announce the Digital Health Breakthrough Network, a new initiative to help early-stage digital health companies validate new prototypes through rapid pilot studies. Administered by industry partner HITLAB, the Breakthrough Network will convene a network of end-users and mimic real-world use conditions, providing the most meaningful data for startups looking to sign beta customers and raise investment.
NYCEDC will tease more information about this new program at the HITLAB Innovator's Summit on December 3 - 4 (see more information below). The HITLAB Innovator's Summit is a signature event of the NYC digital health ecosystem. Registration is open now.
On December 3-4, 2015 in New York City, leaders in public health, medicine, technology, and design will discuss health issues and solutions at the HITLAB Innovators SummitSM. This two-day live event offers a series of carefully curated talks, panels, and collaboration opportunities to engage the most creative minds in health and technology.
The Summit culminates in the final round of the HITLAB World CupSM, an international challenge of unparalleled diversity where innovators present original solutions to pressing global healthcare challenges. Five finalists will present and winners will be awarded funding as well as the opportunity to network with prominent experts.